All updated as on -
Infertility has been a worldwide epidemic during the past few decades. Infertility affects about 10% of women, according to a WHO survey from 2010. The National Institutes of Health found that about 12% of reproductive-aged couples experience fertility issues. Intrauterine Insemination (IUI) dominated the market in 2018 and is expected to rapidly expand in the years to come. The majority of couples start their families this way. In most cases, no anaesthetic or other sedative is necessary for this non-invasive procedure. Because the sperm sample is brought so much closer to the eggs, this method of insemination has a higher success rate than others. Over the forecast period, intravaginal insemination is expected to grow at a rate that places it only behind the fastest-growing segment. This can be done at home or in a specialised reproductive health centre.
Disorders like erectile dysfunction and Polycystic Ovary Syndrome (PCOS) are on the rise, contributing to a rising global rate of infertility. Complications may arise as a result of lifestyle shifts and an increasing trend of career-focused women delaying motherhood. Male infertility is exacerbated by factors such as stress, alcohol intake, lifestyle changes, and a reduction in the number and motility of sperm. The rising prevalence of infertility among both sexes is a key factor propelling the international artificial insemination market.
Artificial insemination is often the first step in treating infertility, even though IVF is the most advanced method of ART. Once upon a time, art was banned due of widespread moral, natural, and ethical concerns. People in the community, including relatives and acquaintances, assessed families with children conceived using assisted reproductive technologies. Artificial insemination procedures are in high demand due to government initiatives and regulatory shifts. In the United States, infertility treatment is covered by health insurance in roughly 14 of the 50 states. The government of Canada is taking action to halt the country's declining population. It has funded a number of in vitro fertilisation and/or artificial insemination procedures, for instance. In addition, up to 40% of the cost of reproductive treatments can be deducted for Canadian taxpayers. Up to six cycles of Intrauterine Insemination (IUI) may be covered by the National Health Service in the United Kingdom.
Access to assisted reproductive technologies (ARTs) like artificial insemination remains challenging in nations with inadequate resources. The WHO estimates that 180 million people around the world experience fertility problems. Your chances of getting pregnant may diminish if you are unable to get a timely diagnosis or treatment for infertility. There is a large gap between the number of people who need reproductive health care and the number of people who actually receive it in developing and emerging countries.
Report Coverage
Global Artificial Insemination research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Artificial Insemination report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Artificial Insemination competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Artificial Insemination market players and analyses their core competencies in each global market sub-segments.
Key Points Covered in the Report
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Artificial Insemination market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Artificial Insemination market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
The leading players in the global artificial insemination market are – Vitrolife, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation, etc. Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC and Vitrolife AB.
Primary Target Market
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Artificial Insemination market based on the below-mentioned segments:
Global Artificial Insemination Market, By Type
Global Artificial Insemination market, By Source
Global Artificial Insemination Market, By Technique
Global Artificial Insemination Market, By End User
Global Artificial Insemination market, Regional Analysis
Disorders like erectile dysfunction and Polycystic Ovary Syndrome (PCOS) are on the rise, contributing to a rising global rate of infertility. Complications may arise as a result of lifestyle shifts and an increasing trend of career-focused women delaying motherhood. Male infertility is exacerbated by factors such as stress, alcohol intake, lifestyle changes, and a reduction in the number and motility of sperm. The rising prevalence of infertility among both sexes is a key factor propelling the international artificial insemination market.
Artificial insemination is often the first step in treating infertility, even though IVF is the most advanced method of ART. Once upon a time, art was banned due of widespread moral, natural, and ethical concerns. People in the community, including relatives and acquaintances, assessed families with children conceived using assisted reproductive technologies. Artificial insemination procedures are in high demand due to government initiatives and regulatory shifts. In the United States, infertility treatment is covered by health insurance in roughly 14 of the 50 states. The government of Canada is taking action to halt the country's declining population. It has funded a number of in vitro fertilisation and/or artificial insemination procedures, for instance. In addition, up to 40% of the cost of reproductive treatments can be deducted for Canadian taxpayers. Up to six cycles of Intrauterine Insemination (IUI) may be covered by the National Health Service in the United Kingdom.
Access to assisted reproductive technologies (ARTs) like artificial insemination remains challenging in nations with inadequate resources. The WHO estimates that 180 million people around the world experience fertility problems. Your chances of getting pregnant may diminish if you are unable to get a timely diagnosis or treatment for infertility. There is a large gap between the number of people who need reproductive health care and the number of people who actually receive it in developing and emerging countries.
Report Coverage
Global Artificial Insemination research report categorizes the market for global based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. Global Artificial Insemination report analyses the key growth drivers, opportunities, and challenges influencing the global market. Recent market developments and Artificial Insemination competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key Artificial Insemination market players and analyses their core competencies in each global market sub-segments.
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2017-2030 |
| Base Year | 2020 |
| Forecast Period | 2022-2030 |
| Historical Period | 2017-2019 |
| Unit | Value (USD Billion) |
| Key Companies Profiled | Vitrolife, Genea Limited, Rinovum Womens Health, Pride Angel, Hi-tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation, etc. Conceivex Inc |
| Segments Covered | • By Product |
| Customization Scope | Free report customization (equivalent to up to 3 analyst working days) with purchase. Addition or alteration to country, regional & segment scope |
Key Points Covered in the Report
- Market Revenue of Artificial Insemination Market from 2021 to 2030.
- Market Forecast for Artificial Insemination Market from 2021 to 2030.
- Regional Market Share and Revenue from 2021 to 2030.
- Country Market share within region from 2021 to 2030.
- Key Type and Application Revenue and forecast.
- Company Market Share Analysis, Artificial Insemination competitive scenario, ranking, and detailed company
profiles. - Market driver, restraints, and detailed COVID-19 impact on Artificial Insemination
Market
Competitive Environment:
The research provides an accurate study of the major organisations and companies operating in the global Artificial Insemination market, along with a comparative evaluation based on their product portfolios, corporate summaries, geographic reach, business plans, Artificial Insemination market shares in specific segments, and SWOT analyses. A detailed analysis of the firms' recent news and developments, such as product development, inventions, joint ventures, partnerships, mergers and acquisitions, strategic alliances, and other activities, is also included in the study. This makes it possible to assess the level of market competition as a whole.
List of Major Market Participants
The leading players in the global artificial insemination market are – Vitrolife, Genea Limited, Rinovum Women's Health, Pride Angel, Hi-tech Solutions, Fujifilm Irvine Scientific, Kitazato Corporation, etc. Conceivex Inc., FUJIFILM Irvine Scientific Inc. (Fujifilm Holdings Corporation), Genea Limited, Genus plc, Hamilton Thorne Inc., Hi-Tech Solutions, Kitazato Corporation, Pride Angel, Rinovum Women’s Health LLC, Rocket Medical plc, TenderNeeds Fertility LLC and Vitrolife AB.
Primary Target Market
- Market Players of Artificial Insemination
- Investors
- End-users
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Third-party knowledge providers
- Value-Added Resellers (VARs)
Market Segment:
This study forecasts global, regional, and country revenue from 2019 to 2030. Spherical Insights has segmented the global Artificial Insemination market based on the below-mentioned segments:
Global Artificial Insemination Market, By Type
- Insemination Kits
- Home Conception Devices
- Accessories
Global Artificial Insemination market, By Source
- AIH - Husband
- AID - Donor
- Others
Global Artificial Insemination Market, By Technique
- Intrauterine Insemination
- Intracervical Insemination
- Intravaginal Insemination Intratubal Insemination
- Intratubal Insemination
Global Artificial Insemination Market, By End User
- Fertility Clinics
- Home
Global Artificial Insemination market, Regional Analysis
- Europe: Germany, Uk, France, Italy, Spain, Russia, Rest of Europe
- The Asia Pacific: China,Japan,India,South Korea,Australia,Rest of Asia Pacific
- South America: Brazil, Argentina, Rest of South America
- Middle East & Africa: UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa
About This Research
You will get in-depth and extensive artificial insemination market market research and competitor analysis for your business to help you develop more profound insights into the artificial insemination market Market.
Through INFINITIVE Data Expert is a professional Market Research services, I will identify the artificial insemination market market size, demand & opportunities, growth rate, and target audience with a comprehensive analysis of your competitors.